Valuing Pharmaceutical Drug Innovations
We propose a methodology to estimate the market value of pharmaceutical drugs. Our approach combines an event study with a model of discounted cash flows and uses stock market responses to drug development announcements to infer the values. We estimate that, on average, a successful drug is valued at \$1.62 billion, and its value at the discovery stage is \$64.3 million, with substantial heterogeneity across major diseases. Leveraging these estimates, we also determine the average drug development costs at various stages. Furthermore, we explore applying our estimates to design policies that support drug development through drug buyouts and cost-sharing agreements.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Valuing Post-Revenue Biopharmaceutical Assets with Pfizer's Current Portfolio as a Case Study
This research paper addresses the critical challenge of accurately valuing post-revenue drug assets in the biotechnology and pharmaceutical sectors, a key factor influencing a wide range of strategic operations and inves…
Decision MakingPrincipal-Agent Hypothesis Testing
Consider the relationship between a regulator (the principal) and an experimenter (the agent) such as a pharmaceutical company. The pharmaceutical company wishes to sell a drug for profit, whereas the regulator wishes to…
Drugst.One -- A plug-and-play solution for online systems medicine and network-based drug repurposing
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and net…
Drug DiscoveryUsing mathematical models of heart cells to assess the safety of new pharmaceutical drugs
Many drugs have been withdrawn from the market worldwide, at a cost of billions of dollars, because of patient fatalities due to them unexpectedly disturbing heart rhythm. Even drugs for ailments as mild as hay fever hav…
BlockingRhythmPredicting effect of novel treatments using molecular pathways and real-world data
In pharmaceutical R&D, predicting the efficacy of a pharmaceutical in treating a particular disease prior to clinical testing or any real-world use has been challenging. In this paper, we propose a flexible and modular m…